Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLCM NASDAQ:MLND NASDAQ:ONCY NASDAQ:OTIC NASDAQ:SCPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLCMBellicum Pharmaceuticals$0.07$0.08$0.06▼$1.31$727K1.3922,874 shs6,059 shsMLNDMillendo Therapeutics$10.26-4.2%$4.00$0.92▼$16.95$195.29M0.481.52 million shs47,473 shsONCYOncolytics Biotech$1.24-3.5%$1.09$0.33▼$1.53$123.95M1.191.01 million shs731,596 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/ASCPHscPharmaceuticals$5.63-0.1%$5.07$1.94▼$6.28$299.81M0.35606,887 shs318,523 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLCMBellicum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MLNDMillendo Therapeutics0.00%-6.69%+8.18%+55.14%+607.24%ONCYOncolytics Biotech0.00%+20.75%+18.52%+99.84%+33.89%OTICOtonomy0.00%0.00%0.00%0.00%0.00%SCPHscPharmaceuticals0.00%+1.08%+22.39%+41.10%+2.55%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLCMBellicum Pharmaceuticals$0.07$0.08$0.06▼$1.31$727K1.3922,874 shs6,059 shsMLNDMillendo Therapeutics$10.26-4.2%$4.00$0.92▼$16.95$195.29M0.481.52 million shs47,473 shsONCYOncolytics Biotech$1.24-3.5%$1.09$0.33▼$1.53$123.95M1.191.01 million shs731,596 shsOTICOtonomy$0.01$0.06$0.01▼$2.54$582K1.54937,525 shsN/ASCPHscPharmaceuticals$5.63-0.1%$5.07$1.94▼$6.28$299.81M0.35606,887 shs318,523 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLCMBellicum Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MLNDMillendo Therapeutics0.00%-6.69%+8.18%+55.14%+607.24%ONCYOncolytics Biotech0.00%+20.75%+18.52%+99.84%+33.89%OTICOtonomy0.00%0.00%0.00%0.00%0.00%SCPHscPharmaceuticals0.00%+1.08%+22.39%+41.10%+2.55%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLCMBellicum Pharmaceuticals 0.00N/AN/AN/AMLNDMillendo Therapeutics 0.00N/AN/AN/AONCYOncolytics Biotech 2.80Moderate Buy$5.00304.86% UpsideOTICOtonomy 0.00N/AN/AN/ASCPHscPharmaceuticals 2.00Hold$7.7838.37% UpsideCurrent Analyst Ratings BreakdownLatest OTIC, MLND, ONCY, BLCM, and SCPH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/29/2025SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$5.358/25/2025SCPHscPharmaceuticalsCraig HallumSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$6.008/25/2025SCPHscPharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold8/13/2025ONCYOncolytics BiotechLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLCMBellicum Pharmaceuticals$1.50M0.48N/AN/A$0.23 per share0.33MLNDMillendo TherapeuticsN/AN/AN/AN/A$1.78 per shareN/AONCYOncolytics BiotechN/AN/AN/AN/A$0.05 per shareN/AOTICOtonomy$130K4.48N/AN/A$0.97 per share0.01SCPHscPharmaceuticals$36.33M8.25N/AN/A$0.27 per share20.83Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLCMBellicum Pharmaceuticals-$24.97MN/A0.00∞N/AN/AN/A-157.93%N/AMLNDMillendo Therapeutics-$36.41MN/A0.00∞N/AN/A-91.03%-72.44%N/AONCYOncolytics Biotech-$23.14M-$0.27N/AN/AN/AN/A-438.11%-143.90%11/11/2025 (Estimated)OTICOtonomy-$51.18M-$0.77N/A∞N/AN/A-137.86%-68.50%N/ASCPHscPharmaceuticals-$85.15M-$1.81N/AN/AN/A-183.55%-1,647.86%-71.76%11/12/2025 (Estimated)Latest OTIC, MLND, ONCY, BLCM, and SCPH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/8/2025Q2 2025ONCYOncolytics Biotech-$0.11-$0.05+$0.06-$0.05N/AN/A8/7/2025Q2 2025SCPHscPharmaceuticals-$0.30-$0.34-$0.04-$0.34$15.41 million$16.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLCMBellicum PharmaceuticalsN/AN/AN/AN/AN/AMLNDMillendo TherapeuticsN/AN/AN/AN/AN/AONCYOncolytics BiotechN/AN/AN/AN/AN/AOTICOtonomyN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLCMBellicum PharmaceuticalsN/A3.043.04MLNDMillendo TherapeuticsN/A6.396.39ONCYOncolytics BiotechN/A2.882.88OTICOtonomyN/A1.741.74SCPHscPharmaceuticals3.863.853.14Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLCMBellicum Pharmaceuticals4.93%MLNDMillendo TherapeuticsN/AONCYOncolytics Biotech6.82%OTICOtonomy41.23%SCPHscPharmaceuticals89.52%Insider OwnershipCompanyInsider OwnershipBLCMBellicum Pharmaceuticals10.30%MLNDMillendo TherapeuticsN/AONCYOncolytics Biotech0.10%OTICOtonomy1.09%SCPHscPharmaceuticals4.78%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLCMBellicum Pharmaceuticals139.72 million8.72 millionNot OptionableMLNDMillendo Therapeutics1219.04 millionN/ANot OptionableONCYOncolytics Biotech30100.36 million100.26 millionNot OptionableOTICOtonomy5168.53 million67.78 millionOptionableSCPHscPharmaceuticals3053.30 million50.75 millionOptionableOTIC, MLND, ONCY, BLCM, and SCPH HeadlinesRecent News About These CompaniesscPharmaceuticals, Inc. (NASDAQ:SCPH) Short Interest UpdateSeptember 11, 2025 | marketbeat.com90,503 Shares in scPharmaceuticals, Inc. $SCPH Bought by Nuveen LLCSeptember 8, 2025 | marketbeat.comscPharmaceuticals, Inc. $SCPH Position Reduced by Deutsche Bank AGSeptember 3, 2025 | marketbeat.comApis Capital Advisors LLC Grows Holdings in scPharmaceuticals, Inc. $SCPHSeptember 2, 2025 | marketbeat.comMannKind diversifies pipeline with $360M buySeptember 2, 2025 | pacbiztimes.comPKingdon Capital Management L.L.C. Buys 200,000 Shares of scPharmaceuticals, Inc. $SCPHSeptember 1, 2025 | marketbeat.comH.C. Wainwright Reiterates a Buy Rating on MannKind Corporation (MNKD)August 31, 2025 | finance.yahoo.comVelan Capital Investment Management LP Makes New Investment in scPharmaceuticals, Inc. $SCPHAugust 31, 2025 | marketbeat.comMaxim Group Reaffirms Hold Rating for scPharmaceuticals (NASDAQ:SCPH)August 27, 2025 | marketbeat.comscPharmaceuticals downgraded to Hold from Buy at MaximAugust 26, 2025 | msn.comSCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ...August 26, 2025 | tmcnet.comSCPHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of scPharmaceuticals Inc. - SCPHAugust 26, 2025 | businesswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates VTLE and SCPH on Behalf of ShareholdersAugust 26, 2025 | globenewswire.comStonepine Capital Management LLC Has $914,000 Stock Holdings in scPharmaceuticals, Inc. $SCPHAugust 26, 2025 | marketbeat.comscPharmaceuticals downgraded to Hold from Buy at Craig-HallumAugust 25, 2025 | msn.comCT maker of therapeutic inhalers agrees to acquire Mass. biopharma company in $360M dealAugust 25, 2025 | hartfordbusiness.comHMannKind grabs scPharmaceuticals and its heart failure infuser Furoscix in $360M dealAugust 25, 2025 | fiercepharma.comFSCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKindAugust 25, 2025 | globenewswire.comSCPH Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of scPharmaceuticals Inc. Is Fair to ShareholdersAugust 25, 2025 | businesswire.comShareholder Alert: The Ademi Firm Investigates Whether scPharmaceuticals Inc. Is Obtaining a Fair Price for Its Public ShareholdersAugust 25, 2025 | businesswire.comMannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung DiseasesAugust 25, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025The Case for Buying NVIDIA Stock Ahead of the Robotics SurgeBy Thomas Hughes | August 20, 2025Nextracker Stock Rockets as AI and Solar Tailwinds AlignBy Thomas Hughes | August 21, 2025The Uber Eats Partnership Fueling Serve Robotics' GrowthBy Jeffrey Neal Johnson | August 28, 2025AEHR Spikes 36% on Hyperscaler Order—Investors Should Take NoticeBy Leo Miller | August 27, 2025OTIC, MLND, ONCY, BLCM, and SCPH Company DescriptionsBellicum Pharmaceuticals NASDAQ:BLCMBellicum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen. Its clinical product candidates also include BPX-603, an autologous dual-switch GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing human epidermal growth factor receptor 2 antigen. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is based in Houston, Texas.Millendo Therapeutics NASDAQ:MLNDAs of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.Oncolytics Biotech NASDAQ:ONCY$1.24 -0.05 (-3.52%) As of 01:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.Otonomy NASDAQ:OTICOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.scPharmaceuticals NASDAQ:SCPH$5.62 -0.01 (-0.09%) As of 01:47 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Wall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
